Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 6Phase 1/2 5Phase 3 2

Status

Recruiting 5Active not recruiting 3Not yet recruiting 2Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 5Recurrence 1Neoplasms, Plasma Cell 1

Interventions

pembrolizumab 109Cyclophosphamide 89fludarabine 70Carboplatin 57Injections 56Bevacizumab 49Specimen Handling 43Gemcitabine 41Magnetic Resonance Spectroscopy 40Paclitaxel 39Nivolumab 38venetoclax 36Dexamethasone 35Cisplatin 34Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Capecitabine 27Oxaliplatin 26Fluorouracil 26Pemetrexed 24Irinotecan 24Azacitidine 24abemaciclib 23toripalimab 22Fulvestrant 22fludarabine phosphate 21Rituximab 21Leucovorin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × iberdomide × Clear all
NCT05583617 2026-06-03

PLYCOM

Hoffmann-La Roche

Phase 1/2 Recruiting
200 enrolled
Plasma cell

Multiple Myeloma

NCT06232044 2026-03-25

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Alliance for Clinical Trials in Oncology

Phase 1/2 Recruiting
88 enrolled
Plasma cell

Multiple Myeloma

NCT05199311 2026-02-18

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

Hackensack Meridian Health

Phase 1/2 Recruiting
66 enrolled
Plasma cell

Multiple Myeloma

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
49 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06785415 2025-09-30

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Mayo Clinic

Phase 1/2 Recruiting
37 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡